MindMed Launches Clinical Trial Focused On Combining LSD With MDMA

Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and LSD. The trials, to be conducted at the University Hospital Basel Liechti Lab in Switzerland, will look to measure and evaluate the effects on the body of the drugs when used in combination with one-another.

MindMed is currently working under the hypothesis that when used in combination, positive side effects of the drugs may improve, including positive mood and empathy, while reducing negative emotions that can be associated with that of LSD. The trial will focus on whether MDMA is able to offset some of these known negative side effects of LSD that can occur in therapy or clinical settings.

The study itself will be conducted as a phase 1 double-blind placebo controlled study, which includes a 4-period crossover design. Within, the trials will evaluate the subjective and autonomic effects with a focus on qualitative emotional differences between four separate experiences: a combination of MDMA and LSD, pure LSD, pure MDMA, and finally a placebo.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

LSD has found in certain phase 1 studies to demonstrate serotonin receptor stimulation, which has lead to ego dissolution and neuroplasticity, which are believed to have therapeutic effects on those suffering from mental disorders. If the study conducted is proven successful, MindMed intends to undertake studies with treatments combining both MDMA and LSD for several potential mental disorders and indications.

The study is anticipated to take roughly one year.

Mind Medicine last traded at $3.83 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Mind Medicine To Raise Further $19.5 Million In Bought Deal

Mind Medicine (NEO: MMED) this morning announced that it is conducting yet another round of...

Monday, March 8, 2021, 07:59:24 AM

Mind Medicine Completes Pre-IND Meeting For LSD Assisted Therapy In Anxiety

Mind Medicine (NEO: MMED) this morning issued a brief update related two products within its...

Monday, December 14, 2020, 07:54:19 AM

MindMed Starts Clinical Trial For Intravenous DMT

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced today the start of...

Wednesday, July 28, 2021, 10:22:00 AM

MindMed Begins Study On LSD Neutralizer Technology

MindMed (NEO: MMED) this morning announced that it has begun a study on what it...

Wednesday, February 17, 2021, 08:18:59 AM

MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to...

Tuesday, October 26, 2021, 10:35:00 AM